Curis Regains Nasdaq Compliance After Reverse Split, But Faces Strict One-Year Monitor

summarizeSummary

Curis regained Nasdaq compliance on July 24, 2026, following its reverse stock split, but is now under a strict one-year monitor where any new deficiency leads to immediate delisting proceedings.

check_boxKey Events · Legal and Risk Events · CRIS

• Nasdaq Compliance Restored

  On July 24, 2026, Curis received written notice from Nasdaq confirming it has regained compliance with the Bid Price Rule, following the 1-for-20 reverse stock split.

• One-Year Discretionary Panel Monitor

  The company is now subject to a Discretionary Panel Monitor for one year. Any new listing deficiency during this period will result in an immediate Delist Determination Letter, with no opportunity for a compliance plan or extension.

• No Grace Period for Future Deficiencies

  Under the monitor, Curis cannot submit a plan of compliance for any new deficiency, and Nasdaq staff cannot grant additional time to regain compliance — a hearing is the only recourse.

• Going-Concern Risk Persists

  The compliance restoration does not address Curis's underlying financial distress: a going-concern warning, no revenue, and a cash runway that remains tight.

auto_awesomeAnalysis · CRIS · Life Sciences

The immediate delisting threat is off the table: Curis has regained compliance with Nasdaq's bid price rule, a direct result of the 1-for-20 reverse stock split executed earlier this month. Yet the relief comes with a catch — the company now operates under a one-year Discretionary Panel Monitor. Any new listing deficiency during this period triggers an automatic delisting determination, with no grace period or compliance plan option. For a firm carrying a going-concern warning, no revenue, and a market cap under $10 million, this monitor period is a tightrope. The compliance restoration is positive, but the stringent monitoring underscores the fragility of Curis's listing status.